Cited by 114Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalus

Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment

Wolfsgruber, Steffen, Polcher, Alexandra, Koppara, Alexander, Kleineidam, Luca, Frölich, Lutz, Peters, Oliver, Hüll, Michael, Rüther, Eckart +6 more·2017·Journal of Alzheimer's Disease

Abstract

BACKGROUND: There is very limited data on the prevalence of abnormal cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) and their predictive value for clinical progression in memory clinic patients with subjective cognitive decline (SCD). OBJECTIVE: To assess the frequency of abnormal CSF biomarkers of AD and their predictive value for clinical progression in memory clinic patients with SCD in comparison to patients with mild cognitive impairment (MCI) from the same cohort. METHODS: We analyzed prospective data from memory clinic patients of the German Competence Network Dementia cohort with a baseline diagnosis of SCD (n = 82) or MCI (n = 134), distinguished by actuarial neuropsychological MCI criteria ("Jak-Bondi criteria"). Risk of clinical progression during 3-year follow-up was evaluated with Cox-Proportional-Hazard models. RESULTS: Prevalence of abnormal values in CSF markers of tau-mediated neurodegeneration (67.8% versus 46.3%) but not of amyloid deposition (40.3% versus 35.4%) was significantly higher in MCI compared to SCD. The rate of incident AD dementia (26.1% versus 12.2%) was also significantly higher in MCI. In SCD, additional 22% progressed to MCI during follow-up. Combined amyloid/tau abnormality was the strongest predictor of clinical progression in both groups. CONCLUSION: High prevalence of biomarker abnormality and clinical progression, together with the predictive value of CSF biomarkers, in memory clinic patients with SCD support the validity and usefulness of this condition as a "pre-MCI" at risk stage of AD.

Integrity signals

Registry

Crossref · 10.3233/jad-161252

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wolfsgruber, S., Polcher, A., Koppara, A., Kleineidam, L., Frölich, L., Peters, O., Hüll, M., Rüther, E., Wiltfang, J., Maier, W., Kornhuber, J., Lewczuk, P., Jessen, F., & Wagner, M.
Affiliations
  • University of Bonn (DE)
  • Central Institute of Mental Health (DE)
  • Stiftung Charité (DE)
  • University of Freiburg (DE)
  • University of Göttingen (DE)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Medical University of Białystok (PL)
  • University of Cologne (DE)
Corresponding author
Wolfsgruber, Steffen
Venue
Journal of Alzheimer's Disease
Published
2017-06-05
Volume
58
Issue
3
Pages
939-950
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2614873104
Cited by
114
References
33
Citations by year
2026: 4 · 2025: 17 · 2024: 19 · 2023: 11 · 2022: 16 · 2021: 16 · 2020: 10 · 2019: 8 · 2018: 9 · 2017: 4
FWCI
6.96
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Alzheimer s Disease (publishedVersion)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • DZNE Pub (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
Keywords
cerebrospinal fluid biomarkers, subjective cognitive decline
MeSH terms
Aged, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Neuropsychological Tests, Peptide Fragments, Phosphorylation, Prospective Studies, Risk Factors, Biomarkers, Incidence, Prevalence, Proportional Hazards Models, Amyloid beta-Peptides, tau Proteins, Disease Progression, Kaplan-Meier Estimate, Diagnostic Self Evaluation, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review